Policy and Practice Review: A First Guideline on the Use of Pharmacogenetics in Clinical Psychiatric Practice.
Policy and Practice Review: A First Guideline on the Use of Pharmacogenetics in Clinical Psychiatric Practice.
复制标题
DOI：
10.3389/fphar.2021.640032
复制
发表时间：
2021
影响因子：
5.6
通讯作者：
van Weelden-Hulshof MJM
中科院分区：
文献类型：
--
作者：
van Westrhenen R;van Schaik RHN;van Gelder T;Birkenhager TK;Bakker PR;Houwink EJF;Bet PM;Hoogendijk WJG;van Weelden-Hulshof MJM
精神疾病的有效药物治疗是可用的，但由于患者的遗传异质性和与频繁不良事件相关的低依从性，其效果有限。只有三分之一的患者对治疗有反应并得到缓解。药物遗传学是一个相对年轻的领域，它侧重于在代谢和药物治疗结果的背景下进行遗传分析。除其他因素外，这些遗传因素会导致代谢药物的酶活性的差异。最近，荷兰临床精神病学协会（NVvP）批准了一项关于药物遗传学在精神病学中的临床应用的临床指南。主要目标是根据目前的证据，就如何在临床精神病学实践中最好地使用基因分型提供指导。进行了系统的文献检索，并使用GRADE方法评估了可用的出版物。提供了精神病学临床实践的一般建议，并对每种药物提出了具体建议。这份精神药物处方护理人员临床指南是来自不同学科的专业人员广泛合作的产物，利用了迄今为止荷兰药物遗传学工作组（DPWG）和临床药物遗传学实施联盟（CPIC）提供的信息。本文对相关文献进行综述，并提出建议。提供了一般建议，也提供了每种药物的详细建议。总之，当CYP2C19和CYP2D6有副作用或无效时，我们建议考虑基因分型。当基因型信息可用时，使用它来为正确的患者选择正确剂量的正确药物。
Effective pharmacologic treatments for psychiatric disorders are available, but their effect is limited due to patients’ genetic heterogeneity and low compliance-related to frequent adverse events. Only one third of patients respond to treatment and experience remission. Pharmacogenetics is a relatively young field which focusses on genetic analyses in the context of the metabolism and outcome of drug treatment. These genetic factors can, among other things, lead to differences in the activity of enzymes that metabolize drugs. Recently, a clinical guideline was authorized by the Dutch Clinical Psychiatric Association (NVvP) on the clinical use of pharmacogenetics in psychiatry. The main goal was to provide guidance, based on current evidence, on how to best use genotyping in clinical psychiatric practice. A systematic literature search was performed, and available publications were assessed using the GRADE methodology. General recommendations for psychiatric clinical practice were provided, and specific recommendations per medication were made available. This clinical guideline for caregivers prescribing psychotropic drugs is the product of a broad collaboration of professionals from different disciplines, making use of the information available at the Dutch Pharmacogenetics Working Group (DPWG) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) so far. We summarize the relevant literature and all recommendations in this article. General recommendations are provided and also detailed recommendations per medication. In summary we advise to consider genotyping, when there are side effects or inefficacy for CYP2C19 and CYP2D6. When genotype information is available use this to select the right drug in the right dose for the right patient.
登录
查看更多内容
DOI：
10.9758/cpn.2015.13.2.150
发表时间：
2015-08-31
期刊：
Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
影响因子：
--
作者：
Singh AB
通讯作者：
Singh AB
影响因子：
4.8
作者：
Greden, John F.;Parikh, Sagar V.;Dechairo, Bryan
通讯作者：
Dechairo, Bryan
影响因子：
6.7
作者：
Zhou Y;Ingelman-Sundberg M;Lauschke VM
通讯作者：
Lauschke VM
影响因子：
4.8
作者：
Bradley, Paul;Shiekh, Michael;Lukowiak, Andrew A.
通讯作者：
Lukowiak, Andrew A.
影响因子：
6.7
作者：
Swen, J. J.;Nijenhuis, M.;Guchelaar, H-J
通讯作者：
Guchelaar, H-J